Drug Trial Radar · NCT04001777
A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
73
Actual
Start
Jul 4, 2019
Primary completion
May 27, 2025
Study completion May 27, 2025
Sponsor
- Lead sponsor
- Ascentage Pharma Group Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Suzhou Yasheng Pharmaceutical Co., Ltd.
- First posted
- Jun 28, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
There are unmet medical needs in patients who resist to EGFR TKIs, especially to osimertinib; APG-1252 shows synergy with osimertinib in both osimertinib treatment naïve and resistant cell lines. This study is to explore the safety and efficacy of the combination of APG-1252 and osimertinib in 3rd generation TKI resistant patients and 3rd generation TKI treatment naïve patients.
Conditions
- EGFR Positive Non-small Cell Lung Cancer
Interventions
APG-1252Drug
Multiple dose cohorts, 30 minute IV infusion, weekly for 3 weeks of a cycle with 21days.
Osimertinib Mesylate TabletsDrug
Osimertinib Mesylate Tablets 40mg/80 mg, one time a day until disease progression
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose (MTD)Time frame: 21 days
- Recommended Phase 2 dose (RP2D)Time frame: 21 days
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Sun-Yat Sen University Cancer Center
Guangzhou, Guangdong, China
Henan Provincial people's Hospital
Zhengzhou, Henan, China
First Hospital of Jilin University
Changchun, Jilin, China
Jilin Provincial Cancer Hospital
Changchun, Jilin, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.